Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397428/
https://www.ncbi.nlm.nih.gov/pubmed/30886737
http://dx.doi.org/10.1136/rmdopen-2018-000692corr1
_version_ 1783399413156151296
collection PubMed
description
format Online
Article
Text
id pubmed-6397428
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-63974282019-03-18 Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors RMD Open Correction BMJ Publishing Group 2019-02-18 /pmc/articles/PMC6397428/ /pubmed/30886737 http://dx.doi.org/10.1136/rmdopen-2018-000692corr1 Text en © Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Correction
Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
title Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
title_full Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
title_fullStr Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
title_full_unstemmed Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
title_short Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
title_sort correction: ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cdmards) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397428/
https://www.ncbi.nlm.nih.gov/pubmed/30886737
http://dx.doi.org/10.1136/rmdopen-2018-000692corr1

Ejemplares similares